Interesting results came from the longitudinal analysis of ctDNA in lung cancer patients receiving inhibitor of epidermal growth factor receptor (EGFR); in 4/21 patients, Kato et al. detected an increase in ctDNA with unique mutations not identified in the initial biopsy [12]. Here, EGFR is linked to lung cancer.